FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:2572-2574 June 11, 2009 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article Related Article by Bolla, M.

Clinicians and researchers have debated the relative efficacy and timing of androgen deprivation since 1941, when Charles B. Huggins and Clarence V. Hodges reported that androgen deprivation reduced testosterone levels and produced dramatic positive therapeutic responses in patients with advanced prostate cancer.¹ By 1966, when Huggins won the Nobel Prize in Physiology or Medicine for this work, many clinicians assumed that castration or treatment with diethylstilbestrol prolonged life and in some instances was curative.

The Veterans Administration Cooperative Urological Research Group (VACURG) trials conducted in the 1960s tested this hypothesis.² The group found that androgen deprivation dramatically relieved the obstructive . . . [Full Text of this Article]

Source Information

From the Division of Urology, University of Connecticut Health Center, Farmington.

This article has been cited by other articles:

• (2009). Short-Term vs. Long-Term Hormone Therapy for Prostate Cancer. JWatch Oncology and Hematology 2009: 1-1 [Full Text]